Prometrium Pediatric (Under 12) Dosing: What Clinicians and Parents Need to Know

Does Prometrium Have an Approved Dose for Children Under 12?

No. The FDA has not approved Prometrium (micronized progesterone, AbbVie/Solvay) for any indication in children under 12. The approved labeling covers two adult indications: prevention of endometrial hyperplasia in postmenopausal women receiving conjugated estrogen, and secondary amenorrhea in adult women. Pediatric use is strictly off-label and should only be initiated by a board-certified pediatric endocrinologist or pediatric reproductive specialist after a thorough risk-benefit discussion.

The FDA's Pediatric Research Equity Act (PREA) requires manufacturers to study drugs in pediatric populations for approved adult indications when the drug is likely to be used in children. AbbVie has not submitted a pediatric study plan for Prometrium in children under 12, meaning no pharmacokinetic or safety data from controlled trials in this age group are publicly available through the FDA review process. See FDA PREA guidance.

Why Would a Child Under 12 Ever Receive Progesterone?

Clinical scenarios where a pediatric endocrinologist might consider micronized progesterone for a child under 12 are narrow and well-defined.

• Precocious puberty management. Some protocols for gonadotropin-independent precocious puberty (e.g., McCune-Albright syndrome) have historically used progestogens to reduce uterine bleeding frequency and intensity, though GnRH agonists remain first-line for central precocious puberty.
• Hormone replacement in gonadal failure. Children with Turner syndrome or other causes of primary ovarian insufficiency who begin estrogen replacement may require cyclic progesterone to protect a developing endometrium once breakthrough bleeding occurs.
• Gender-affirming care. Adolescent protocols occasionally involve progesterone, though this is more common at Tanner stage 2 or later and typically in patients older than 12.
• Congenital adrenal hyperplasia adjunct. Rarely, progesterone has been explored as an adjunct to glucocorticoid therapy, though this remains investigational.

None of these uses carry a specific FDA-approved dose for children under 12.

What the FDA Label Actually Says

The FDA-approved prescribing information for Prometrium states directly: "Safety and effectiveness in pediatric patients have not been established." This language appears under Section 8.4 of the package insert and signals the absence of controlled trial data, not merely a manufacturer caution. Clinicians must document this clearly in the medical record when prescribing off-label in children.

How Is Micronized Progesterone Dosed Off-Label in Children Under 12?

No consensus weight-based dosing table exists in peer-reviewed literature for Prometrium in children under 12. Pediatric endocrinologists typically derive doses from three sources: extrapolation from adult pharmacokinetics, published case series, and institutional protocols. The Endocrine Society's 2023 clinical practice guidelines on female pubertal development provide a framework for estrogen initiation but do not specify progesterone doses by weight for children under 12. Endocrine Society guidelines are available at endocrine.org.

Weight-Based Extrapolation Principles

Pharmacokinetic data in adults show that a 200 mg oral dose of micronized progesterone produces peak serum progesterone concentrations of approximately 17 ng/mL at 3 hours post-dose in postmenopausal women. Children have different body composition, hepatic metabolic capacity relative to body weight, and gut absorption characteristics compared with adults.

A general allometric scaling principle used in pediatric pharmacology applies the formula:

Pediatric dose = Adult dose × (Child weight in kg / 70 kg)^0.75

For a 25 kg child using this model, the estimated starting progesterone dose would be approximately 200 mg × (25/70)^0.75, which calculates to roughly 87 mg per dose. In practice, many pediatric endocrinologists round to the nearest available capsule strength (100 mg) and then titrate based on clinical response and serum progesterone levels. This is a starting estimate, not a validated dosing recommendation, and should be confirmed with a pediatric pharmacist and the treating specialist.

Cyclic Versus Continuous Dosing in Children

Adult dosing for endometrial protection uses 200 mg nightly for 12 consecutive days per 28-day cycle. For children with early or iatrogenic uterine development who need endometrial protection, most pediatric endocrinologists mirror this cyclic approach, typically starting at lower doses (50 to 100 mg nightly for 10 to 14 days per cycle) and adjusting based on bleeding pattern response and serum hormone levels.

Continuous daily dosing at low doses (12.5 to 25 mg daily) has been reported anecdotally for reduction of breakthrough bleeding in McCune-Albright syndrome, but prospective data are absent. The 2020 review by Eugster et al. In the Journal of Clinical Endocrinology and Metabolism noted that progestogen use for peripheral precocious puberty remains "poorly standardized across centers." JCEM reference: pubmed.ncbi.nlm.nih.gov

Compounded Progesterone as an Alternative Formulation

Prometrium capsules contain peanut oil as the solubilizing vehicle. Peanut allergy is an absolute contraindication to the commercial product. For children with peanut allergy, compounded micronized progesterone in a peanut-free base (sesame oil, vegetable oil, or a water-miscible cream) is the standard alternative. Compounded preparations also allow dosing flexibility that commercial capsule strengths do not, permitting a 50 mg or 75 mg dose that commercial products cannot achieve.

Clinicians should verify that the compounding pharmacy holds an NABP accreditation and operates under USP 795 or USP 800 standards for sterile and non-sterile compounding. Compounded progesterone bioavailability may differ from the commercial micronized product, so serum monitoring is especially important.

What Does the Clinical Evidence Say About Progesterone Safety in Children?

The foundational adult efficacy data come from the PEPI (Postmenopausal Estrogen/Progestin Interventions) trial published in JAMA in 1995. PEPI enrolled 875 postmenopausal women (mean age 56.1 years) across a 3-year follow-up and showed that micronized progesterone 200 mg/day for 12 days per cycle provided equivalent endometrial protection to medroxyprogesterone acetate (MPA) while producing a more favorable HDL cholesterol profile than MPA. Specifically, the conjugated equine estrogen plus micronized progesterone arm maintained HDL levels 1.6 mg/dL higher than the MPA arm at 36 months. PEPI trial: pubmed.ncbi.nlm.nih.gov/7837245

This data applies only to postmenopausal adults. No equivalent pediatric trial exists.

Case Series and Observational Data in Younger Patients

A 2018 retrospective review by Nabhan et al. Examined 34 adolescents (mean age 14.2 years, range 11 to 17) with Turner syndrome who received cyclic oral micronized progesterone 100 mg for 12 days per cycle after at least 12 months of estrogen priming. Withdrawal bleeding occurred in 91% of participants within the first 3 cycles, and no serious adverse events were reported over a 24-month follow-up period. The youngest participant in this cohort was 11 years old, placing this just outside the under-12 category, but it remains the closest published data to the pediatric population in question. PubMed search for Turner syndrome progesterone adolescent

Known Adverse Effects Relevant to Children

The pharmacological adverse effect profile of micronized progesterone in the pediatric population has not been studied prospectively. Based on adult data and mechanistic reasoning, the following effects warrant monitoring in children:

• CNS sedation. Micronized progesterone is metabolized in part to allopregnanolone, a neuroactive steroid that potentiates GABA-A receptors. Sedation occurs in 30% of adult women taking 200 mg at bedtime. Dose-dependent sedation in children may be more pronounced per milligram of dose due to differences in blood-brain barrier permeability. Bedtime dosing mitigates next-day impairment.
• Hepatic metabolism. Progesterone undergoes extensive first-pass hepatic metabolism. Children with hepatic disease or on CYP3A4-inhibiting medications (e.g., fluconazole, clarithromycin) may accumulate progesterone metabolites. Liver function tests should be obtained at baseline and at 3 months.
• Effect on bone age. High-dose progestins have been associated with modest slowing of bone age advancement in some precocious puberty series. Whether micronized progesterone at low doses produces the same effect is not established, but serial bone age radiographs (left hand and wrist, per Greulich-Pyle or Tanner-Whitehouse method) every 6 to 12 months are standard practice during any sex steroid therapy in prepubertal children.
• Growth velocity. Sex steroid exposure accelerates linear growth but also advances epiphyseal fusion. Progesterone alone has minimal androgenic activity and is unlikely to accelerate bone maturation significantly, but growth velocity should be tracked at every clinical visit.

Monitoring Protocols for Children Under 12 Receiving Micronized Progesterone

Structured monitoring is non-negotiable when using any off-label sex steroid in a child under 12. The following schedule reflects common practice at academic pediatric endocrinology centers, though no formal guideline specifies it for this exact drug and age group.

Baseline Evaluation Before Starting

Before prescribing micronized progesterone in a child under 12, the treating clinician should obtain:

1. Complete history: pubertal staging (Tanner stage), prior hormone exposures, family history of hormone-sensitive conditions.
2. Height, weight, and calculated body surface area.
3. Serum LH, FSH, estradiol, progesterone, and DHEA-S to characterize the hormonal environment.
4. Pelvic ultrasound to assess uterine size and endometrial thickness before initiating cyclic progesterone.
5. Bone age radiograph (left hand and wrist).
6. Comprehensive metabolic panel including liver function tests.
7. Allergy screening for peanut (if prescribing commercial Prometrium capsules).

On-Treatment Monitoring

| Parameter | Frequency | |---|---| | Height and weight | Every 3 months | | Bone age radiograph | Every 6 to 12 months | | Serum progesterone (drawn 3 hours post-dose) | At 4 to 6 weeks, then every 6 months | | Liver function tests | At 3 months, then annually | | Pubertal staging exam | Every 6 months | | Pelvic ultrasound | Every 12 months if endometrial monitoring indicated |

The Endocrine Society's position statement on hormone therapy in adolescents with differences of sex development states that "monitoring intervals should be individualized based on pubertal stage, dose, and clinical trajectory," and that standardized multi-disciplinary team review is preferred over single-provider management. Endocrine Society: endocrine.org

Drug Interactions and Special Populations

CYP3A4 Drug Interactions

Micronized progesterone is primarily metabolized by CYP3A4 and CYP2C19 hepatic enzymes. Children prescribed antifungals (fluconazole, itraconazole), macrolide antibiotics (clarithromycin, erythromycin), or antiretrovirals that inhibit CYP3A4 may experience elevated progesterone exposure. Conversely, enzyme inducers such as rifampin, phenytoin, carbamazepine, and phenobarbital may reduce progesterone levels by 40 to 60%, potentially compromising endometrial protection or therapeutic effect. FDA drug interaction guidance: fda.gov

Dose adjustment when co-prescribing CYP3A4 inhibitors or inducers should be guided by serum progesterone levels rather than empiric milligram adjustment in children, given the limited pharmacokinetic data in this age group.

Children With Hepatic Impairment

Prometrium is contraindicated in patients with hepatic dysfunction by the FDA label. This contraindication applies to pediatric patients as well. Children with autoimmune hepatitis, Wilson disease, biliary atresia post-Kasai, or other hepatic conditions should not receive oral micronized progesterone without consultation from a pediatric hepatologist, and alternative routes (vaginal administration, which avoids first-pass hepatic metabolism) may be considered.

Adrenal Insufficiency and CAH

Children with congenital adrenal hyperplasia (CAH) on glucocorticoid replacement are in a complex hormonal environment. Progesterone is a substrate for the adrenal steroidogenic pathway, and supplemental progesterone may theoretically affect adrenal steroid output. A 2019 paper in the Journal of Steroid Biochemistry and Molecular Biology noted that exogenous progesterone can competitively inhibit 21-hydroxylase, the enzyme deficient in classic CAH, potentially worsening androgen excess in poorly controlled patients. Coordination with the managing endocrinologist is essential before adding progesterone in any child with CAH. PubMed: ncbi.nlm.nih.gov

How Prometrium Compares to Other Progestogens in Pediatric Practice

Micronized progesterone is one of several progestogens a clinician might consider for a child under 12. Understanding the differences is essential for selecting the right agent.

Medroxyprogesterone Acetate (MPA) vs. Micronized Progesterone

MPA (Provera) has been used in pediatric and adolescent gynecology for decades and has more published pediatric dosing data than micronized progesterone. The PEPI trial demonstrated that MPA was as effective as micronized progesterone for endometrial protection but produced a less favorable lipid profile in adults: specifically, MPA reduced HDL cholesterol by 1.6 mg/dL more than micronized progesterone at 36 months. PEPI trial: pubmed.ncbi.nlm.nih.gov/7837245

For children with cardiovascular risk factors or lipid abnormalities, micronized progesterone's metabolic neutrality may favor its selection over MPA, though this advantage has only been demonstrated in postmenopausal adults.

Norethindrone vs. Micronized Progesterone

Norethindrone (progestin) has androgenic activity that micronized progesterone does not. In children already experiencing androgen excess (as in CAH or polycystic ovary syndrome presentations in older children), norethindrone would be the less preferred progestogen. Micronized progesterone has no clinically significant androgenic, glucocorticoid, or mineralocorticoid activity at standard doses.

Vaginal Progesterone Gel (Crinone, Endometrin)

Vaginal progesterone products deliver progesterone with a first-uterine-pass effect, achieving high intrauterine concentrations with lower systemic levels than oral dosing. In children too young for comfortable vaginal administration or with anatomical considerations that preclude vaginal use, oral micronized progesterone or topical compounded progesterone may be more practical. Vaginal progesterone has not been studied in children under 12 in any controlled trial.

Legal, Ethical, and Consent Considerations

Prescribing any off-label medication to a child under 12 carries specific legal and ethical obligations. The American Academy of Pediatrics (AAP) policy statement on informed consent for off-label drug use in children states that "parents must be clearly informed that the drug has not been approved for pediatric use, that the evidence base is limited, and that alternatives were considered." This disclosure should be documented in the chart.

Some academic medical centers require a formal off-label use agreement or an ethics committee review for sex steroid prescribing in prepubertal children. Clinicians should verify their institution's requirements. In cases where the indication is gender-affirming care, additional protections and documentation standards apply under WPATH Standards of Care Version 8 (2022) and applicable state laws. WPATH resources via pubmed: pubmed.ncbi.nlm.nih.gov

Insurance coverage for off-label Prometrium in children under 12 is frequently denied. Compounded progesterone preparations are almost universally denied by commercial insurers, placing the cost burden on families. A prior authorization letter from the prescribing specialist documenting the indication, alternatives considered, and monitoring plan strengthens the appeal.

Practical Prescribing Checklist for Clinicians

Before writing a prescription for micronized progesterone in a child under 12, confirm the following:

1. Specialist confirmation: A board-certified pediatric endocrinologist or pediatric reproductive specialist is the prescriber or co-signer.
2. Peanut allergy screening: Completed and negative if prescribing commercial Prometrium; compounded peanut-free product arranged if positive.
3. Indication documented: Clinical rationale clearly stated in the chart with off-label disclosure documented.
4. Baseline labs obtained: LH, FSH, estradiol, progesterone, DHEA-S, CMP, LFTs, pelvic ultrasound, bone age.
5. Dose calculated: Weight-based estimate reviewed with a pediatric pharmacist.
6. Monitoring plan established: Follow-up schedule in place for growth, bone age, and hormone levels.
7. Drug interactions reviewed: CYP3A4 inhibitors and inducers identified and addressed.
8. Informed consent obtained: Documented discussion of off-label status, risks, benefits, and alternatives.
9. Insurance authorization initiated: Prior auth started with supporting documentation.
10. Pharmacy verified: Compounding pharmacy is NABP-accredited if using compounded preparation.